What question did this study set out to answer?

This review aims to evaluate the efficacy and safety of stem cell therapy for type 1 diabetes mellitus (T1DM).

Efficacy and safety of stem cell therapy in type 1 diabetes: A systematic review and meta-analysis of randomised controlled trials

View Full Paper

Ask AI

Bookmark

This review aims to evaluate the efficacy and safety of stem cell therapy for type 1 diabetes mellitus (T1DM).
Conducted a systematic review and meta-analysis of randomized controlled trials (RCTs)
Primary outcome was glycated haemoglobin (HbA1c) levels
Included studies published until January 2025 with seven RCTs involving 169 participants.
Stem cell therapy showed a marginal reduction in HbA1c at 6 months (MD: -0.57%, 95% CI: -1.13 to -0.02)
Fasting C-peptide levels improved slightly at both 6 months (0.03, 0.03 to 0.03) and 12 months (0.09, 0.05 to 0.13)
No participants achieved insulin independence or experienced serious adverse events.

No takes yet. Share an insight, caveat, or question.

Systematic review assesses efficacy and safety of stem cell therapy in T1DM, suggesting limited clinical significance.

Yadav et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark